Recently, Quebec’s Financial Market Authority issued a decision banning any investment in the activities of TachoEasy, a company that provides geolocation “trackers” for cars or valuables such as handbags or precious parcels. The company has experienced rapid success with its business model which consists of actively involving consumers in communication and strategic development efforts. There […]
DOD could only provide financial information for “40% of $2.2 billion” in CERP funds used in Afghanistan report says
I received an email from Alex Bronstein-Moffly – the Director of Public Affairs Special Inspector General for Afghanistan Reconstruction (SIGAR) that he has published a report looking at spending for the Commander’s Emergency Response Program (CERP) in Afghanistan from 2004-2014. The CERP report notes : –The Department of Defense (DoD)could only provide financial information for 40% of $2.2 billion […]
The global community is ready to grant a financial aid to Ukraine and welcomes chosen path towards proper economic reforms and anticorruption efforts.
The global community actively discusses a financial aid to Ukraine. The issue of financial aid to Ukraine was one of the topical at the G-20 summit in Sydney. Ukrainian issue stirred up all international politicians. Such a potential grantors of Ukraine as the EU, the USA and the IMF expressed willingness to help Ukraine. The […]
MolMed Interim Financial Report 2013 Approved
The Board of Directors of MolMed S.p.A., chaired by Prof. Claudio Bordignon, today reviewed and approved the interim financial report at 30 September 2013. The most important elements were: TK: expansion in the US of the pivotal Phase III trial for high-risk leukaemia patients; NGR-TNF: continuation of the clinical development program; the increase of revenues […]
MolMed TK: MolMed Board of Directors approves the first half-year 2013 financial report
TK: new data presented at ASCO 2013 show that the TK therapy enabled the execution of haploidentical donor transplants, with an overall survival similar to transplants from fully compatible donors NGR-hTNF: presented at ASCO 2013 final data from a randomised Phase II study indicating a 50% reduction in the risk of death in first-line treatment […]
MolMed NGR-hTNF: MolMed Board of Directors approves the interim financial report at 31 March 2013
The Board of Directors of MolMed S.p.A. (MLM.MI), chaired by Prof. Claudio Bordignon, today reviewed and approved the interim financial report at 31 March 2013. The most important elements were: progress on dossier preparation to file a market authorisation application for TK through the Conditional Marketing Authorisation procedure with the European Medicines Agency; continuation of ongoing […]
- 1
- 2
- 3
- …
- 39
- Next Page »